Albireo to Present at 2020 Jefferies Virtual Healthcare Conference

BOSTON, May 26, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc.(Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer, will present via webcast at the 2020 Jefferies Virtual Healthcare Conference on Tuesday, June 2, at 8:30 a.m. EDT.

Metadata
Provider: 
GlobeNewswire, Inc.GlobeNewswire, Inc.
Retrieved on: 
Tuesday, May 26, 2020
Information
Tags: 
Stars, Hepatology, Astronomical objects, Stellar astronomy, Albireo, Liver, Bile
Geotags: 
Boston, Ma, Us
Organisation: 
ALBIREO PHARMA, INC.
Summary
Key Points: 
  • BOSTON, May 26, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc.(Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer, will present via webcast at the 2020 Jefferies Virtual Healthcare Conference on Tuesday, June 2, at 8:30 a.m. EDT.
  • The live webcast of the presentation will be accessible from the Media & Investors page of Albireos website, ir.albireopharma.com .
  • To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time.
  • Albireo was spun out fromAstraZenecain 2008.Albireo Pharmais located inBoston, Mass., and its key operating subsidiary is located inGothenburg, Sweden.


BOSTON, May 26, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer, will present via webcast at the 2020 Jefferies Virtual Healthcare Conference on Tuesday, June 2, at 8:30 a.m. EDT.

The live webcast of the presentation will be accessible from the Media & Investors page of Albireo’s website, ir.albireopharma.com. To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time. An archived version of the webcast will be available for replay in the Events & Presentations section of the Media & Investors page of Albireo’s website for at least two weeks following the event.

About Albireo
Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat orphan pediatric liver diseases, and other liver and gastrointestinal diseases and disorders. Albireo’s lead product candidate, odevixibat, is being developed to treat rare pediatric cholestatic liver diseases and is in Phase 3 development in progressive familial intrahepatic cholestasis (PFIC) and biliary atresia. Albireo’s clinical pipeline also includes two Phase 2 product candidates. Elobixibat is in Phase 2 development in NAFLD and NASH. Approved in Japan for the treatment of chronic constipation, elobixibat is the first ileal bile acid transporter (IBAT) inhibitor approved anywhere in the world.

Albireo was spun out from AstraZeneca in 2008. Albireo Pharma is located in Boston, Mass., and its key operating subsidiary is located in Gothenburg, Sweden. The Boston Business Journal named Albireo one of the 2019 Best Places to Work in Massachusetts. For more information on Albireo, please visit www.albireopharma.com.

Investor Contact: Hans Vitzthum, LifeSci Advisors, LLC, 617-430-7578
Media Contact: Claire LaCagnina, 6 Degrees, 315-765-1462, [email protected]

Source: Albireo Pharma, Inc.

 

Primary Logo
Copyright: 
2020 GlobeNewswire, Inc.. All Rights Reserved.